Literature DB >> 17665017

[Crouzon syndrome: factors related to the neuropsychological development and to the quality of life].

Adriano Yacubian-Fernandes1, Luis Gustavo Ducati, Mateus Violin Silva, Dagma Venturini Marques Abramides, Gimol B Perosa, Aristides Palhares, Roberto C Gabarra, Alcir Giglio, Luis Portela, João Luiz P Marinello, José Píndaro P Plese, Silvio Antonio Zanini.   

Abstract

Crouzon syndrome is characterized by cranial and facial abnormalities and exophtalmos. Mental retardation is sometimes observed. The objective of this study was to correlate brain malformations, timing for surgery and also social classification of families and parents education to the neuropsychological evaluation and to the quality of life of these families. Eleven patients with Crouzon syndrome were studied, whose ages were between 16 and 132 months. The multidisciplinary evaluation included : social evaluation, cognitive evaluation, brain studies by magnetic resonance imaging and quality of life evaluation. The intelligence quotient values observed were between 46 and 102 (m=84.2) and was correlated (inverted correlation) to the factor IV of the short-form of the Questionnaire on Resources and Stress. Mental development was not correlated to brain malformation, neither to the age at time of operation or to the level of family environment and parents education.

Entities:  

Mesh:

Year:  2007        PMID: 17665017     DOI: 10.1590/s0004-282x2007000300020

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  2 in total

1.  Crouzon's syndrome: tooth morphological and microanalytical evaluation.

Authors:  R Pawlicki; Z Knychalska-Karwan; D Darczuk; T Nowak
Journal:  Eur Arch Paediatr Dent       Date:  2008-12

2.  Health-related problems and quality of life in patients with syndromic and complex craniosynostosis.

Authors:  Tim de Jong; Marianne Maliepaard; Natalja Bannink; Hein Raat; Irene M J Mathijssen
Journal:  Childs Nerv Syst       Date:  2012-01-11       Impact factor: 1.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.